Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorBenha University

About this trial

This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.

Eligibility criteria

Qualifiers

IPSS score > 20

Uroflowmetry flow rate < 10 ml/sec

Post-void residual > 150 cc

PSA level between 4 and 20 ng/ml

Disqualifiers

Patient PSA level > 20 ng/ml

More than 3 focal lesions on MP-MRI

Metastatic prostate cancer

History of lower urinary tract surgery (e.g., TURP, Laser, urinary diversions, artificial urinary sphincter)

Trial design

Treatments tested in this trial

  • Bioblation

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators